Efficacy and Safety of Using Cilostazol Versus Aspirin in Secondary Stroke Prevention: Systematic Review and Meta-analysis of Randomised Controlled Clinical Trials

Overview

Journal Intern Med J

Specialty General Medicine

Date 2025 Mar 6

PMID 40047064

Authors

Ping Zhuang

Yi-Min Huang

Zhenyong Zheng

Xiaodie Zhang

Affiliations

Soon will be listed here.

Abstract

Background: Secondary stroke prevention is crucial for reducing recurrent events and associated morbidity. Cilostazol, a phosphodiesterase III inhibitor, is considered an alternative to aspirin for patients with ischaemic stroke due to its potentially lower risk of haemorrhagic complications. This meta-analysis evaluates the efficacy and safety of cilostazol versus aspirin for secondary stroke prevention. It provides a basis for drug selection and observation of secondary stroke prevention strategies.

Methods: A comprehensive search was conducted in PubMed, Cochrane Library, EMBASE and Web of Science databases for randomised controlled trials comparing cilostazol with aspirin in secondary stroke prevention. Key outcomes included recurrence of ischaemic stroke, intracranial haemorrhage (ICH), death, effective rate and incidence of adverse events. Meta-analysis was performed using a random-effects model, and heterogeneity was assessed using I statistics and Cochran's Q test. Publication bias was evaluated using Doi plots and Luis Furuya-Kanamori index.

Results: Thirteen studies involving 8993 participants were included. Cilostazol significantly reduced the recurrence of ischaemic stroke (risk ratio (RR): 0.766, 95% confidence interval (CI): 0.624-0.941) and ICH (RR: 0.392, 95% CI: 0.250-0.616) compared to aspirin. No significant differences were observed in overall mortality or adverse events. Cilostazol increased risks of headache, dizziness, diarrhoea and tachycardia but reduced constipation. Heterogeneity was generally low to moderate.

Conclusion: Cilostazol is an effective alternative to aspirin for secondary stroke prevention, reducing the risk of recurrent ischaemic stroke and ICH. However, its use is associated with certain adverse effects. Clinicians should consider individual patient profiles and preferences when selecting anti-platelet therapy for stroke prevention. Further research is warranted to optimise cilostazol use in clinical practice.

References

Motta N, Autran L, Brazao S, de Oliveira Lopes R, Scaramello C, Lima G . Could cilostazol be beneficial in COVID-19 treatment? Thinking about phosphodiesterase-3 as a therapeutic target. Int Immunopharmacol. 2021; 92:107336. PMC: 7768212. DOI: 10.1016/j.intimp.2020.107336. View

Singh R, Chen S, Ganesh A, Hill M . Long-term neurological, vascular, and mortality outcomes after stroke. Int J Stroke. 2018; 13(8):787-796. DOI: 10.1177/1747493018798526. View

Shi L, Pu J, Xu L, Malaguit J, Zhang J, Chen S . The efficacy and safety of cilostazol for the secondary prevention of ischemic stroke in acute and chronic phases in Asian population--an updated meta-analysis. BMC Neurol. 2014; 14:251. PMC: 4301843. DOI: 10.1186/s12883-014-0251-7. View

de Havenon A, Sheth K, Madsen T, Johnston K, Turan T, Toyoda K . Cilostazol for Secondary Stroke Prevention: History, Evidence, Limitations, and Possibilities. Stroke. 2021; 52(10):e635-e645. PMC: 8478840. DOI: 10.1161/STROKEAHA.121.035002. View

Han Y, Li Y, Wang S, Jing Q, Wang Z, Wang D . Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: a randomized, controlled study. Am Heart J. 2009; 157(4):733-9. DOI: 10.1016/j.ahj.2009.01.006. View

Rogers K, Oliphant C, Finks S . Clinical efficacy and safety of cilostazol: a critical review of the literature. Drugs. 2015; 75(4):377-95. DOI: 10.1007/s40265-015-0364-3. View

Rothlisberger J, Ovbiagele B . Antiplatelet therapies for secondary stroke prevention: an update on clinical and cost-effectiveness. J Comp Eff Res. 2015; 4(4):377-84. PMC: 5549663. DOI: 10.2217/cer.15.22. View

Sohn M, Lim S . The Role of Cilostazol, a Phosphodiesterase-3 Inhibitor, in the Development of Atherosclerosis and Vascular Biology: A Review with Meta-Analysis. Int J Mol Sci. 2024; 25(5). PMC: 10932209. DOI: 10.3390/ijms25052593. View

Kanlop N, Chattipakorn S, Chattipakorn N . Effects of cilostazol in the heart. J Cardiovasc Med (Hagerstown). 2011; 12(2):88-95. DOI: 10.2459/JCM.0b013e3283439746. View

10.

Cattaneo M . Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance. Arterioscler Thromb Vasc Biol. 2004; 24(11):1980-7. DOI: 10.1161/01.ATV.0000145980.39477.a9. View

11.

Chai E, Chen J, Li C, Zhang X, Fan Z, Yang S . The Efficacy and Safety of Cilostazol vs. Aspirin for Secondary Stroke Prevention: A Systematic Review and Meta-Analysis. Front Neurol. 2022; 13:814654. PMC: 8885726. DOI: 10.3389/fneur.2022.814654. View

12.

Huang E, Strate L, Ho W, Lee S, Chan A . Long-term use of aspirin and the risk of gastrointestinal bleeding. Am J Med. 2011; 124(5):426-33. PMC: 3086018. DOI: 10.1016/j.amjmed.2010.12.022. View

13.

Huang Y, Chen S, Leng X, Kuo K, Wang Z, Cui M . Post-Stroke Cognitive Impairment: Epidemiology, Risk Factors, and Management. J Alzheimers Dis. 2022; 86(3):983-999. DOI: 10.3233/JAD-215644. View

14.

Kherallah R, Khawaja M, Olson M, Angiolillo D, Birnbaum Y . Cilostazol: a Review of Basic Mechanisms and Clinical Uses. Cardiovasc Drugs Ther. 2021; 36(4):777-792. DOI: 10.1007/s10557-021-07187-x. View

15.

Lin M, Meschia J, Gopal N, Barrett K, Ross O, Ertekin-Taner N . Cilostazol Versus Aspirin for Secondary Stroke Prevention: Systematic Review and Meta-Analysis. J Stroke Cerebrovasc Dis. 2021; 30(3):105581. DOI: 10.1016/j.jstrokecerebrovasdis.2020.105581. View

16.

Flora G, Nayak M . A Brief Review of Cardiovascular Diseases, Associated Risk Factors and Current Treatment Regimes. Curr Pharm Des. 2019; 25(38):4063-4084. DOI: 10.2174/1381612825666190925163827. View

17.

McHutchison C, Blair G, Appleton J, Chappell F, Doubal F, Bath P . Cilostazol for Secondary Prevention of Stroke and Cognitive Decline: Systematic Review and Meta-Analysis. Stroke. 2020; 51(8):2374-2385. PMC: 7382534. DOI: 10.1161/STROKEAHA.120.029454. View

18.

Hiatt W, Money S, Brass E . Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: A Study in Long-term Effects). J Vasc Surg. 2007; 47(2):330-336. DOI: 10.1016/j.jvs.2007.10.009. View

19.

Bath P, Wardlaw J . Pharmacological treatment and prevention of cerebral small vessel disease: a review of potential interventions. Int J Stroke. 2015; 10(4):469-78. PMC: 4832291. DOI: 10.1111/ijs.12466. View

20.

Mac Grory B, Yaghi S, Cordonnier C, Sposato L, Romano J, Chaturvedi S . Advances in Recurrent Stroke Prevention: Focus on Antithrombotic Therapies. Circ Res. 2022; 130(8):1075-1094. PMC: 9015232. DOI: 10.1161/CIRCRESAHA.121.319947. View